JSPR · Jasper Therapeutics, Inc.
$0.60
-0.03 (-5.15%)
At close · Jul 29
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.”View the 10-Q filed May 14, 2026
Market Cap
$17.72M
Shares
28.00M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$75.8
+100%
FY2025
Diluted EPS
-$3.95
+19.2%
FY2025
Operating Cash Flow
-$77.16M
-23.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| — | — | — | -$246K | — | -$80K | — | — | |
| — | $41.64M | — | — | — | — | — | — | |
| $52.76M | $63.1M | $55.82M | $51.79M | $34.63M | $25.42M | — | — | |
| $20.27M | $20.78M | $20.42M | $17.08M | $16.57M | $11.41M | $935.4K | $136.3K | |
| — | $1.06M | $1.37M | $1.11M | $975K | $377K | — | — | |
| $73.03M | $83.88M | $76.24M | $68.86M | $51.2M | $36.83M | — | — | |
| -$10.95M | -$83.88M | -$76.24M | -$68.86M | -$51.2M | -$36.83M | -$935.4K | -$136.3K | |
| $1.28M | $1.74M | $5.06M | $5.2M | — | — | — | — | |
| $17.3M | $8.08M | $4.97M | — | $586K | — | — | — | |
| -$2.57M | — | — | — | — | — | -$6.44M | $18.27K | |
| — | $2000 | $2000 | — | — | — | $38.45K | $16.23K | |
| -$1.17M | -$75.8 | -$71.3M | -$64.5M | -$37.69M | -$30.64M | -$6.48M | $2043 | |
| — | — | -$71.27M | — | — | -$30.64M | — | — | |
| USD/shares | -$0.04 | -$3.95 | -$4.89 | -$6.18 | -$10.30 | — | — | — |
| USD/shares | -$0.04 | -$3.95 | -$4.89 | -$6.18 | -$10.30 | — | — | — |
| shares | 28.67M | 19.17M | 14.58M | 10.44M | 3.65M | 1.14M | — | — |
| shares | 28.67M | 19.17M | 14.58M | 10.44M | 3.65M | 1.14M | — | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 19.47×
EV/EBIT
—
P/E (TTM)
—
Peer median 0.17×
Peer medians compare against the 234 similar-size Biotechnology companies (of 522 listed).